Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. more
Time Frame | CNTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.17% | 0.31% | -1.26% |
1-Month Return | -27.2% | 0.6% | -4.16% |
3-Month Return | -50.25% | -9.44% | -0.46% |
6-Month Return | -55% | -5.15% | 3.58% |
1-Year Return | -13.15% | 0.33% | 22.47% |
3-Year Return | -56% | 4.53% | 25.13% |
5-Year Return | -80.59% | 35.98% | 77.7% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | 9.27K | 12.04K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":76.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | - | - | (9.27K) | (12.04K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-926800,"profit":false},{"date":"2023-12-31","value":-1204400,"profit":false}] |
Gross Margin | - | - | - | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 5.38M | 2.57M | 7.44M | 14.88M | 25.07M | [{"date":"2019-12-31","value":21.45,"profit":true},{"date":"2020-12-31","value":10.26,"profit":true},{"date":"2021-12-31","value":29.67,"profit":true},{"date":"2022-12-31","value":59.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (5.38M) | (2.57M) | (10.53M) | (15.38M) | (25.07M) | [{"date":"2019-12-31","value":-537714400,"profit":false},{"date":"2020-12-31","value":-257216800,"profit":false},{"date":"2021-12-31","value":-1052581900,"profit":false},{"date":"2022-12-31","value":-1538120300,"profit":false},{"date":"2023-12-31","value":-2507261600,"profit":false}] |
Total Non-Operating Income/Expense | (2.11M) | 8.56M | 4.71K | 1.09M | 2.38M | [{"date":"2019-12-31","value":-24.63,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.06,"profit":true},{"date":"2022-12-31","value":12.77,"profit":true},{"date":"2023-12-31","value":27.77,"profit":true}] |
Pre-Tax Income | (6.38M) | 6.64M | (10.46M) | (14.84M) | (23.96M) | [{"date":"2019-12-31","value":-96.08,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-157.38,"profit":false},{"date":"2022-12-31","value":-223.28,"profit":false},{"date":"2023-12-31","value":-360.66,"profit":false}] |
Income Taxes | 1.10M | 661.22K | (3.02M) | (545.26K) | (4.00) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":60.09,"profit":true},{"date":"2021-12-31","value":-274.77,"profit":false},{"date":"2022-12-31","value":-49.55,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (7.48M) | 5.98M | (7.43M) | (14.29M) | (23.96M) | [{"date":"2019-12-31","value":-125.09,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-124.23,"profit":false},{"date":"2022-12-31","value":-238.85,"profit":false},{"date":"2023-12-31","value":-400.52,"profit":false}] |
Income From Continuous Operations | (6.38M) | 6.64M | (10.46M) | (14.84M) | (20.75M) | [{"date":"2019-12-31","value":-96.08,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-157.38,"profit":false},{"date":"2022-12-31","value":-223.28,"profit":false},{"date":"2023-12-31","value":-312.31,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (7.48M) | 6.64M | (7.43M) | (14.29M) | (23.96M) | [{"date":"2019-12-31","value":-112.64,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-111.87,"profit":false},{"date":"2022-12-31","value":-215.08,"profit":false},{"date":"2023-12-31","value":-360.66,"profit":false}] |
EPS (Diluted) | - | - | (1.16) | (0.93) | (1.50) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-116,"profit":false},{"date":"2022-12-31","value":-93,"profit":false},{"date":"2023-12-31","value":-150,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CNTX | |
---|---|
Cash Ratio | 36.36 |
Current Ratio | 36.91 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CNTX | |
---|---|
ROA (LTM) | -19.19% |
ROE (LTM) | -29.68% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CNTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.03 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.97 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CNTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.92 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 1.60 |
Context Therapeutics Inc (CNTX) share price today is $0.9901
Yes, Indians can buy shares of Context Therapeutics Inc (CNTX) on Vested. To buy Context Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CNTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Context Therapeutics Inc (CNTX) via the Vested app. You can start investing in Context Therapeutics Inc (CNTX) with a minimum investment of $1.
You can invest in shares of Context Therapeutics Inc (CNTX) via Vested in three simple steps:
The 52-week high price of Context Therapeutics Inc (CNTX) is $2.75. The 52-week low price of Context Therapeutics Inc (CNTX) is $0.89.
The price-to-earnings (P/E) ratio of Context Therapeutics Inc (CNTX) is
The price-to-book (P/B) ratio of Context Therapeutics Inc (CNTX) is 0.92
The dividend yield of Context Therapeutics Inc (CNTX) is 0.00%
The market capitalization of Context Therapeutics Inc (CNTX) is $74.26M
The stock symbol (or ticker) of Context Therapeutics Inc is CNTX